<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04593420</url>
  </required_header>
  <id_info>
    <org_study_id>A-FR-52014-241</org_study_id>
    <nct_id>NCT04593420</nct_id>
  </id_info>
  <brief_title>Treatment of Aggressive Prostate Cancer in Real Life: Initiation, Schedule and Management of Triptorelin Treatment.</brief_title>
  <acronym>TALISMAN</acronym>
  <official_title>Treatment of Aggressive Prostate Cancer in Real Life: Initiation, Schedule and Management of Triptorelin Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the protocol is to describe the proportion of subjects treated continuously&#xD;
      with triptorelin during 12 months following treatment initiation. This study will take place&#xD;
      at 170 locations (approximately) in France.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects treated continuously with triptorelin for the 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>The proportion of subjects treated continuously with triptorelin for the 12 months following treatment initiation, with any formulation and any route of administration. The treatment status (i.e. patient continuously treated / patient not continuously treated) will be assessed according to the investigator's judgment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Planned total duration of triptorelin treatment</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary reasons of choice of planned total triptorelin treatment duration</measure>
    <time_frame>baseline, 6 month, 12 months</time_frame>
    <description>Description of the primary reason of choice of planned total triptorelin treatment duration declared by the investigator, at V1; and at V2 and V3 if the planned total duration is modified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parameters that influence the planned total duration of triptorelin treatment</measure>
    <time_frame>Baseline</time_frame>
    <description>Identification of parameters that influence the planned total duration of triptorelin treatment including but not limited to the following parameters: Circumstance of prescription, Prostate Cancer (PCa) aggressiveness criteria, Prior PCa treatments, Concomitant PCa treatments, Subject's characteristics: age, weight, Karnofsky score, specific comorbidities and concomitant treatments, genetic predisposition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parameters that influence the modification of the planned total duration of triptorelin treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Identification of parameters that influence the modification (if any) of the planned total duration of triptorelin treatment including but not limited to the following parameters: PCa aggressiveness criteria at 12 months (PSA, concomitant treatments for prostate cancer, symptoms, metastases assessment), Subject's characteristics: age, weight, Karnofsky score, specific comorbidities and concomitant treatments, genetic predisposition at baseline, follow up assessments, care pathway.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Formulation and administration route of triptorelin prescribed</measure>
    <time_frame>baseline, 6 and 12 months</time_frame>
    <description>Formulation and administration route of triptorelin prescribed (monthly intramuscular, 3-monthly subcutaneous, 3-monthly intramuscular, 6-monthly intramuscular).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the reasons of choice of formulation and administration route of triptorelin prescribed</measure>
    <time_frame>baseline</time_frame>
    <description>monthly intramuscular, 3-monthly subcutaneous, 3-monthly intramuscular, 6-monthly intramuscular) at V1, according to the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parameters that influence the choice of formulation and administration route of triptorelin prescribed</measure>
    <time_frame>baseline</time_frame>
    <description>Identification of parameters that influence the choice of formulation and administration route of triptorelin prescribed (monthly intramuscular, 3-monthly subcutaneous, 3-monthly intramuscular, 6-monthly intramuscular) at V1 including but not limited to the following parameters: Disease with symptoms, total planned duration of treatment, highly evolutive disease, heavy PCa concomitant treatment, physical frailty of subjects, psychological context of subjects, potential impact on compliance, subject afraid of injection, anticoagulant treatment, BMI, Preferred investigator formulation/route</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description and change at each follow-up visit from baseline</measure>
    <time_frame>baseline, 6 months, 12 months</time_frame>
    <description>Description and change at each follow-up visit (V2, V3) from baseline (V1) in each of the 6 sub-scales of the QLQ-PR25 questionnaire (urinary symptoms, incontinence aid, bowel symptoms; treatment related symptoms, sexual activity, sexual functioning). QLQ-PR25 score is distributed from 1 (not at all) to 4 (very much).</description>
  </secondary_outcome>
  <enrollment type="Anticipated">786</enrollment>
  <condition>Prostate Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        786 subjects presenting a prostate cancer histologically confirmed and eligible to start&#xD;
        triptorelin treatment for at least 12 months will be included in the study. They should&#xD;
        also be able to complete a self-questionnaire.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years old&#xD;
&#xD;
          -  Histologically confirmed prostate cancer&#xD;
&#xD;
          -  Triptorelin to be initiated in its labelled indication for a planned total duration of&#xD;
             at least 12 months; decision to start triptorelin was made voluntarily by the&#xD;
             physician as part of routine medical practice, prior to the inclusion in the study&#xD;
&#xD;
          -  Ability to understand and complete questionnaire,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously received a hormonal therapy during the last 6 months before inclusion,&#xD;
&#xD;
          -  Simultaneously participates in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ipsen Recruitment Enquiries</last_name>
    <phone>see email</phone>
    <email>clinical.trials@ipsen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ipsen Central Contact</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

